Cardio-renal syndrome (CRS) is a term referring to a bidirectional group of disorders in which there is a concomitant compromise of both organs, the heart and the kidney, leading to a significant increase in morbidity and mortality. In recent years, numerous publications have addressed this complex entity from different points of view. For better understanding, five subtypes have been established: depending on its form of presentation, acute or chronic; the organ initially affected; and whether there is another responsible systemic disease. CRS represents a complex interaction between both organs with several neurohormonal, inflammatory, and hemodynamic pathophysiological mechanisms involved. Because of its heterogeneous presentation and complex management, CRS requires a multidisciplinary approach targeting multiple pathogenic mechanisms. Throughout this review, we will analyze all relevant aspects of CRS from its classification to current diagnosis and treatment. Accordingly, this review provides a holistic overview of cardio-renal syndrome, emphasizing integrated pathophysiological mechanisms, contemporary diagnostic approaches, and their relevance for clinical management.
Heart transplantation remains the gold standard for the treatment of advanced heart failure (HF). Identification of the etiology of HF is mandatory, as the specific pathology can determine subsequent treatment. Early identification of familial hypercholesterolemia (FH), the most common genetic disorder associated with premature cardiovascular disease, has a potential important impact on clinical management and public health. We evaluated the genetic information in the genes associated with FH in a cohort of 140 heart-transplanted patients. All patients underwent NGS genetic testing including LDLR, APOB, and PCSK9. We identified four carriers of rare pathogenic variants in LDLR and APOB. Although all four identified carriers had dyslipidemia, only the one carrying the pathogenic variant LDLR c.676T>C was transplanted due to CAD. Another patient with heart valvular disease was carrier of the controversial LDLR c.2096C>T. Two additional patients with non-ischemic dilated cardiomyopathy were carriers of variants in APOB (c.4672A>G and c.5600G>A). In our cohort, we identified the genetic cause of FH in patients that otherwise would not have been diagnosed. Opportunistic genetic testing for FH provides important information to perform personalized medicine and risk stratification not only for patients but also for relatives at concealed high cardiovascular risk. Including the LDLR gene in standard NGS cardiovascular diagnostics panels should be considered.
Introduction: Basal cardiovascular risk assessment in cardio-oncology is essential. Integrating clinical information, ECG and transthoracic echocardiogram can identify concealed inherited cardiomyopathies (ICMPs) with potential added risk of cardiotoxicity. We aimed to evaluate the impact of our Cardio-Oncology Unit design in detecting concealed ICMPs. Methods: We carried out a retrospective study of all consecutive breast cancer patients referred to the Cardio-Oncology Unit for cardiac evaluation (2020–2022). ICMPs diagnosis was provided according to ESC guidelines and underwent genetic testing. ICMPs prevalence in this cohort was compared to the highest and lowest frequency reported in the general population. Results: Among 591 breast cancer patients, we identified eight patients with ICMPs: one arrhythmogenic cardiomyopathy (ACM), three familial non-ischemic dilated cardiomyopathy (DCM), three hypertrophic cardiomyopathy (HCM) and one left ventricular non-compaction cardiomyopathy (LVNC), which has now been reclassified as non-dilated left ventricular cardiomyopathy. The number of ICMPs identified was within the expected range (neither overdiagnosed nor overlooked): ACM 0.0017 vs. 0.0002–0.001 (p 0.01–0.593); DCM 0.0051 vs. 0.002–0.0051 (p 0.094–0.676); HCM 0.005 vs. 0.0002–0.002 (p < 0.001–0.099); LVCN 0.0017 vs. 0.00014–0.013 (p 0.011–0.015). Genetic testing identified a pathogenic FLNC variant and two pathogenic TTN variants. Conclusion: Opportunistic screening of ICMPs during basal cardiovascular risk assessment can identify high-risk cancer patients who benefit from personalized medicine and enables extension of prevention strategies to all available relatives at concealed high cardiovascular risk.
Cardio-renal syndrome (CRS) is a term referring to a bidirectional group of disorders in which there is a concomitant compromise of both organs, the heart and the kidney, leading to a significant increase in morbidity and mortality. In recent years, numerous publications have addressed this complex entity from different points of view.For better understanding, five subtypes have been established: depending on its form of presentation, acute or chronic; the organ initially affected and whether there is another responsible systemic disease.CRS represents a complex interaction between both organs with several neurohormonal, inflammatory and hemodynamic pathophysiological mechanisms involved. Its different forms of presentation and the difficulty of its management requires a multidisciplinary and comprehensive therapeutic approach targeting all the mechanisms involved in its pathogenesis. Throughout this review we will analyze all relevant aspects of CRS from its classification to current diagnosis and treatment.